Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection
Open accessPublished version of a preprint
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Ivermectin is an antiparasitic drug being investigated for repurposing against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Ivermectin showed in vitro activity against SARS-COV-2, but only at high concentrations. This meta-analysis investigated ivermectin in 23 randomized clinical trials (3349 patients) identified through systematic searches of PUBMED, EMBASE, MedRxiv, and trial registries. The primary meta-analysis was carried out by excluding studies at a high risk of bias. Ivermectin did not show a statistically significant effect on survival (risk ratio [RR], 0.90; 95% CI, 0.57 to 1.42; P = .66) or hospitalizations (RR, 0.63; 95% CI, 0.36 to 1.11; P = .11). Ivermectin displayed a borderline significant effect on duration of hospitalization in comparison with standard of care (mean difference, –1.14 days; 95% CI, –2.27 to –0.00; P = .05). There was no significant effect of ivermectin on time to clinical recovery (mean difference, –0.57 days; 95% CI, –1.31 to 0.17; P = .13) or binary clinical recovery (RR, 1.19; 95% CI, 0.94 to 1.50; P = .15). Currently, the World Health Organization recommends the use of ivermectin only inside clinical trials. A network of large clinical trials is in progress to validate the results seen to date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Mehra, M. R., Ruschitzka, F., & Patel, A. N. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31324-6 · Cited by 553 · cited 2×
“A previous study of hydroxychloroquine for COVID-19 was retracted from The Lancet [52], leading to changes in procedures for publication in The Lancet [53].”
RetractedCochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Dexamethasone in Hospitalized Patients with Covid-19
The RECOVERY Collaborative Group (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2021436 · Cited by 11,477
Effect of Dexamethasone in Hospitalized Patients with COVID-19 – Preliminary Report
Horby, P., Lim, W. S., Emberson, J., Mafham, M., Bell, J., Linsell, L., Staplin, N., Brightling, C., Ustianowski, A., Elmahi, E., et al. (2020) · doi:10.1101/2020.06.22.20137273 · Cited by 11,475
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Henry, B. M., de Oliveira, M. H. S., Benoit, S., Plebani, M., & Lippi, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0369 · Cited by 1,964
Interleukin-6 receptor antagonists in critically ill patients with Covid-19.
The REMAP-CAP Investigators (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2100433 · Cited by 1,962
Hashim, H. A., Maulood, M. F., Rasheed, A. M., Fatak, D. F., Kabah, K. K., & Abdulamir, A. S. (2020) · doi:10.1101/2020.10.26.20219345 · Cited by 98
Research works printed but not linked: 43
- RECOVERY Collaborative Group, 2021, Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 397, 1637, 10.1016/S0140-6736(21)00676-0 · DOI · Paper page
- WHO Solidarity Trial Consortium, 2021, Repurposed antiviral drugs for Covid-19—interim WHO solidarity trial results, N Engl J Med, 384, 497, 10.1056/NEJMoa2023184 · DOI · Paper page
- Mahase, 2021, Covid-19: budesonide shortens recovery time in patients not admitted to hospital, study finds, BMJ, 373, n957, 10.1136/bmj.n957 · doi:10.1136/bmj.n957
- Caly, 2020, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res, 178, 104787, 10.1016/j.antiviral.2020.104787 · DOI · Paper page
- Arshad, 2020, Prioritization of anti-SARS-Cov-2 drug repurposing opportunities based on plasma and target site concentrations derived from their established human pharmacokinetics, Clin Pharmacol Ther, 108, 775, 10.1002/cpt.1909 · DOI
- Schmith, 2020, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Ther, 108, 762, 10.1002/cpt.1889 · DOI · Paper page
- Jermain, 2020, Development of a minimal physiologically-based pharmacokinetic model to simulate lung exposure in humans following oral administration of ivermectin for COVID-19 drug repurposing, J Pharm Sci, 109, 3574, 10.1016/j.xphs.2020.08.024 · DOI
- González Canga, 2008, The pharmacokinetics and interactions of ivermectin in humans—a mini-review, AAPS J, 10, 42, 10.1208/s12248-007-9000-9 · DOI · Paper page
- Zhang, 2009, Inhibitory effects of ivermectin on nitric oxide and prostaglandin E2 production in LPS-stimulated RAW 264.7 macrophages, Int Immunopharmacol, 9, 354, 10.1016/j.intimp.2008.12.016 · DOI
- Ci, 2009, Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway, Fundam Clin Pharmacol, 23, 449, 10.1111/j.1472-8206.2009.00684.x · DOI
- Zhang, 2008, Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice, Inflamm Res, 57, 524, 10.1007/s00011-008-8007-8 · DOI · Paper page
- Ventre, 2017, Topical ivermectin improves allergic skin inflammation, Allergy, 72, 1212, 10.1111/all.13118 · DOI
- Yan, 2011, Anti-inflammatory effects of ivermectin in mouse model of allergic asthma, Inflamm Res, 60, 589, 10.1007/s00011-011-0307-8 · DOI
- de Melo, 2021, Anti-COVID-19 efficacy of ivermectin in the golden hamster, EMBO Mol Med
- Zaidi, 2021, The mechanisms of action of ivermectin against SARS-CoV-2: an evidence-based clinical review article, J Antibot, 10.1038/s41429-021-00430-5 · DOI
- Navarro, 2020, Safety of high-dose ivermectin: a systematic review and meta-analysis, J Antimicrob Chemother, 75, 827, 10.1093/jac/dkz524 · DOI
- Tzou, 2020, Coronavirus antiviral research database (CoV-RDB): an online database designed to facilitate comparisons between candidate anti-coronavirus compounds, Viruses, 12, 1006, 10.3390/v12091006 · DOI · Paper page
- Shakhsi Niaee, Invermectin as an adjunct treatment for hospitalized adult COVID-19 patients: a randomized, multi-center clinical trial, Asian Pac J Trop Med 2021; 14:266–73
- Mahmud, Ivermectin in combination with doxycycline for treating COVID-19 symptoms: a randomized trial, J Int Med Res, 49
- Mohan, Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial, 2021. doi:10.21203/rs.3.rs-191648/v1 · DOI
- Chaccour, 2021, The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: a pilot, double-blind, placebo-controlled, randomized clinical trial, EClinicalMedicine, 32, 100720, 10.1016/j.eclinm.2020.100720 · DOI · Paper page
- Gonzalez, 2021, Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19, A randomized controlled trial
- Shahbaznejad, 2021, Effects of ivermectin in patients With COVID-19: a multicenter, double-blind, randomized, controlled clinical trial, Clin Ther
- Podder, 2021, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-centre, open-label, randomized controlled study, IMC J Med Sci, 14, 11, 10.3329/imcjms.v14i2.52826 · DOI
- Shah Bukhari, Efficacy of ivermectin in COVID-19 patients with mild to moderate disease, 10.1101/2021.02.02.21250840 · DOI
- Chowdhury, A randomised trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID19 patients, 2020. doi:
- Vallejos, Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial, BMC Infect Dis 2021; 21:635.
- López-Medina, 2021, Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: a randomized clinical trial, JAMA, 325, 1426, 10.1001/jama.2021.3071 · DOI · Paper page
- Krolewiecki, 2021, Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial, Eclinicalmedicine, 37, 100959, 10.1016/j.eclinm.2021.100959 · DOI
- Babalola, 2021, Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind, dose-response study in Lagos, QJM-Int J Med, 10.1093/qjmed/hcab035 · DOI · Paper page
- Galan, 2021, Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection, Pathog Glob Health, 115, 235, 10.1080/20477724.2021.1890887 · DOI
- Abd-Elsalam, 2021, Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study, J Med Virol, 93, 5833, 10.1002/jmv.27122 · DOI · Paper page
- Ahmed, 2021, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis, 103, 214, 10.1016/j.ijid.2020.11.191 · DOI · Paper page
- Okumuş, 2021, Evaluation of the effectiveness and safety of adding ivermectin to treatment in severe COVID-19 patients, BMC Infect Dis, 21, 411, 10.1186/s12879-021-06104-9 · DOI
- Zeeshan Khan Chachar, 2020, Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci, 09, 31
- Chahla, Cluster randomised trials - ivermectin repurposing For COVID-19 treatment of outpatients with mild disease in primary health care centers, 2021. doi:10.21203/rs.3.rs-495945/v1 · DOI
- Elgazzar, Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic, 2020. doi:10.21203/rs.3.rs-100956/v3 · DOI · Paper page
- The Editors of the Lancet Group, 2020, Learning from a retraction, Lancet, 396, 1056, 10.1016/S0140-6736(20)31958-9 · DOI
- Day, 2020, Covid-19: experts criticise claim that remdesivir cuts death rates, BMJ, 370, m2839, 10.1136/bmj.m2839 · doi:10.1136/bmj.m2839
- Wang, 2016, Ivermectin induces PAK1-mediated cytostatic autophagy in breast cancer, Autophagy, 12, 2498, 10.1080/15548627.2016.1231494 · doi:10.1080/15548627.2016.1231494
- Ghazy, 2020, A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment, Sci Rep, 10, 22139, 10.1038/s41598-020-77748-x · DOI
- Alhumaid, 2020, Efficacy and safety of lopinavir/ritonavir for treatment of COVID-19: a systematic review and meta-analysis, Trop Med Infect Dis, 5, 180, 10.3390/tropicalmed5040180 · DOI
- RECOVERY Collaborative Group, 2020, Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Lancet, 396, 1345, 10.1016/S0140-6736(20)32013-4 · DOI · Paper page
Cited by
Bryant, A., Lawrie, T. A., Dowswell, T., Fordham, E. J., Mitchell, S., Hill, S. R., & Tham, T. C. (2021) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001402 · Cited by 264
Ivermectin for preventing and treating COVID-19
Popp, M., Reis, S., Schießer, S., Hausinger, R. I., Stegemann, M., Metzendorf, M.-I., Kranke, P., Meybohm, P., Skoetz, N., & Weibel, S. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015017.pub3 · Cited by 169
Weibel, S., Popp, M., Reis, S., Skoetz, N., Garner, P., & Sydenham, E. (2023) · Research Synthesis Methods · doi:10.1002/jrsm.1599 · Cited by 93
The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable
Lawrence, J. M., Meyerowitz-Katz, G., Heathers, J. A. J., Brown, N. J. L., & Sheldrick, K. A. (2021) · Nature Medicine · doi:10.1038/s41591-021-01535-y · Cited by 88
Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud
Hill, A., Mirchandani, M., & Pilkington, V. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab645 · Cited by 57
Self-citation
Metadata
- Authors
- Hill, A., Garratt, A., Levi, J., Falconer, J., Ellis, L., McCann, K., Pilkington, V., Qavi, A., Wang, J., & Wentzel, H.
- Venue
- Open Forum Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2021-07-06
- Volume
- 8
- Issue
- 11
- Pages
- ofab358-ofab358
- ISSN
- 2328-8957 (ISSN-L)
- OpenAlex
- W3121596699
- Cited by
- 90
- References
- 8
- FWCI
- 2.97
- Type
- journal article
- Language
- en
- Status
- Retracted
- Open access
- gold
- Funders
- Rainwater Charitable Foundation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection. https://app.cochat.ai/papers/10.1093/ofid/ofab358
- The paper
- Hill, A., Garratt, A., Levi, J., Falconer, J., Ellis, L., McCann, K., Pilkington, V., Qavi, A., Wang, J., & Wentzel, H. (2021). Retracted: Meta-analysis of Randomized Trials of Ivermectin to Treat SARS-CoV-2 Infection. Open Forum Infectious Diseases. https://doi.org/10.1093/ofid/ofab358
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.